Article Text

Download PDFPDF
5PSQ-076 Patient-reported outcomes in multiple sclerosis
  1. A Garcia Sacristan1,
  2. P López Sánchez2,
  3. JM Martínez Sesmero1,
  4. H Quiros Ambel1,
  5. A Dominguez Barahona1,
  6. S Gonzalez Suarez1,
  7. P Moya Gomez1
  1. 1Hospital Virgen de la Salud, Pharmacy, Toledo, Spain
  2. 2Hospital de Tomelloso, Pharmacy, Tomelloso, Spain


Background Multiple sclerosis (MS) is a chronic neurological disease that carries important personal, social and economic consequences for patients and their environment. Hospital pharmacists are responsible for effective and safe use of drugs, but also to improve Quality of Life (QoL) and therefore, it is important to evaluate QoL factors related, such as patient satisfaction and activation (or having the knowledge, skills and confidence to manage one’s health, to be related to health-related outcomes).

Purpose The aim is to measure MS patients’ satisfaction with their medication and the patient activation level.

Material and methods Observational, prospective and analytical study, carried out in two hospitals from June 2017 to September 2017. Two validated questionnaires (Treatment Satisfaction Questionnaire for Medication version 1.7 – TQSM1.7: effectiveness score 0–21 points, adverse events score 0–21 points, convenience score 0–21 points, global satisfaction 0–17 points – and Patient Activation Measure questionnaire – PAM: 0–100 points) were completed by MS patients attending the Outpatient Pharmacy Department. We collected the patients’ electronic medical record: sex, age, date of diagnosis, drug treatment, MS type (relapsing remitting MS-RRMS or secondary progressive MS-SPMS) and Expanded Disability Status Scale (EDSS). Statistical analysis was performed using SPSS®21.

Results One hundred and three patients (35.9% males, 64.1% females) answered the questionnaires, mean age 42.67 years (23–65 years). Treatment: 17.5% interferon-B-1a im, 16.5% interferon-B-1a sc, 4.9% peginterferon-B-1a, 9.7% interferon-B-1b, 13.6% glatiramer acetate, 8.7% dimetilfumarate, 13.6% fingolimod, 3.9% teriflunomide, 7.8% natalizumab, 3.9% fampridine. Median treatment duration was 46.94 months (3–216) and 53.4% were MS treatment-naïve. MS types 93.2% RRMS and median EDSS=2.2.

TQSM1.7: average value of effectiveness was 14.3, 13.95 in adverse effects (60 patients answered, the rest did not report adverse effects), 14.26 in convenience and 13.3 in global satisfaction. PAM: 19.4% were classified in level 1, 26.2% in level 2, 41.7% in level 3% and 11.7% in level 4.

Conclusion There is a low patient activation level (45.6% are in levels 1 and 2), however global satisfaction is high (13.3). Effectiveness and convenience of treatment are well valued. As pharmacists it is necessary to identify which groups of patients are the least activated and make a special emphasis on increasing their involvement with the disease to improve health outcomes.

References and/or Acknowledgements No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.